Mitoxantrone is an anthracenedione chemotherapy agent that occupies an important role in veterinary oncology, particularly in the management of feline lymphoma and certain carcinomas. For owners of cats diagnosed with cancer and beginning chemotherapy, understanding what mitoxantrone is, how it works, what the treatment process involves, and how to recognise and manage adverse effects is essential for informed decision-making and effective supportive care at home.

This article provides a comprehensive guide to mitoxantrone use in cats — from its mechanism of action and clinical indications through treatment protocols, monitoring requirements, adverse effect management, and what owners can realistically expect at each stage of treatment.

What Is Mitoxantrone?

Mitoxantrone (also spelled mitoxantrone, trade name Novantrone) is a synthetic anthracenedione — a compound structurally related to the anthracycline antibiotic doxorubicin (Adriamycin), but with a distinct chemical structure that confers a somewhat different adverse effect profile. Like doxorubicin, it intercalates into DNA (inserts itself between DNA base pairs), inhibits topoisomerase II (an enzyme essential for DNA replication and repair), and generates reactive oxygen species that damage both DNA and cell membranes, ultimately triggering apoptosis (programmed cell death) in rapidly dividing cells.

Because rapidly dividing cells are most vulnerable, mitoxantrone preferentially affects tumour cells — but also affects normal rapidly dividing tissues including bone marrow, gastrointestinal epithelium, and hair follicles. This accounts for its adverse effect profile.

Mitoxantrone vs. Doxorubicin in Cats Doxorubicin carries a well-established risk of cumulative dose-dependent nephrotoxicity in cats (distinct from the cardiotoxicity seen in humans and dogs). Mitoxantrone causes significantly less nephrotoxicity than doxorubicin in feline patients and has therefore become a preferred option when an anthracycline-class drug is indicated for cats, particularly those with any degree of renal impairment.

Clinical Indications in Cats

Feline Lymphoma

Mitoxantrone is most commonly used in feline oncology as a component of combination chemotherapy protocols for high-grade (large-cell) lymphoma. It is incorporated into modified CHOP-type protocols and COP protocols, typically as a substitute for or addition to doxorubicin. Its use is generally reserved for:

• High-grade GI or multicentric lymphoma: In combination with vincristine, cyclophosphamide, and prednisolone (COP + mitoxantrone protocols).
• Rescue therapy: For cats that have relapsed after first-line chlorambucil-based therapy for low-grade lymphoma or failed a previous chemotherapy protocol.
• Mediastinal lymphoma: Combination protocols including mitoxantrone are used for mediastinal disease, particularly when doxorubicin is avoided due to renal concerns.

Other Feline Cancers

• Transitional cell carcinoma (TCC) of the bladder: Mitoxantrone combined with piroxicam has shown activity against feline TCC and is the most commonly used systemic protocol for this tumour type.
• Squamous cell carcinoma (SCC): Used in multimodal protocols for oral and nasal SCC, though response rates are modest.
• Mammary carcinoma: Incorporated into combination protocols for metastatic mammary cancer.

Treatment Protocol

Dose and Schedule

Standard mitoxantrone dosing in cats is 6 to 6.5 mg/m2 intravenously, administered every 3 weeks. Body surface area (m2) is calculated from body weight using validated veterinary formulae. The 3-week interval allows recovery of bone marrow function between cycles.

Treatment is typically administered over 4 to 6 cycles, with response assessment — by physical examination, imaging (ultrasound or radiographs), and haematological monitoring — performed before each cycle. In cats achieving complete or partial remission, additional cycles may be continued. In cats not responding after 2 cycles, protocol modification or transition to rescue therapy is considered.

What Happens at a Treatment Session

Understanding the treatment day process helps owners and cats prepare and reduces anxiety. A typical treatment visit involves:

1. Pre-treatment assessment: Physical examination including body weight (essential for dose calculation), assessment of general condition, and review of any adverse signs from the previous cycle.
2. Pre-treatment blood work: A complete blood count (CBC) is performed before each cycle to assess neutrophil and platelet counts. If the absolute neutrophil count (ANC) falls below a safe threshold (typically 2,000 cells/uL), treatment is delayed until haematological recovery. Biochemistry (kidney and liver function) is checked at baseline and periodically throughout the protocol.
3. IV catheter placement: A peripheral intravenous catheter is placed, typically in the cephalic vein of a front leg.
4. IV fluid pre-loading: A bolus of intravenous saline is administered to ensure adequate hydration and reduce the risk of drug concentration effects on the vein wall.
5. Drug administration: Mitoxantrone is administered as a slow intravenous infusion, typically over 5 to 10 minutes. Unlike some chemotherapy agents, mitoxantrone infusion is generally well tolerated in cats in terms of acute reactions.
6. Post-infusion flush: The catheter is flushed with saline to ensure complete drug delivery and prevent local irritation.
7. Monitoring period: The cat is observed for 15 to 30 minutes post-infusion for immediate adverse reactions before discharge.

Vesicant Properties Mitoxantrone is a vesicant — it causes severe tissue damage if it leaks outside the vein (extravasation). If extravasation is suspected during administration (swelling, pain, or resistance at the injection site), infusion must be stopped immediately. Prompt treatment with cold compresses and veterinary intervention minimises tissue damage. This is why mitoxantrone must always be administered through a well-placed IV catheter by trained personnel.

Adverse Effects

Modern veterinary chemotherapy in cats aims to keep adverse effects manageable while preserving quality of life. Most cats tolerate mitoxantrone better than owners fear. However, adverse effects do occur and owners must know what to expect and when to seek veterinary attention.

Myelosuppression (Bone Marrow Suppression)

The most clinically important and potentially serious adverse effect of mitoxantrone is myelosuppression — suppression of bone marrow activity leading to reduced production of white blood cells, red blood cells, and platelets. Neutropenia (reduced neutrophil count) is the primary concern, reaching its nadir (lowest point) approximately 7 to 10 days after each treatment cycle.

Neutropenic cats are immunocompromised and vulnerable to opportunistic infections that a healthy immune system would normally control. Signs of infection in a neutropenic cat — fever above 39.5°C (103.1°F), sudden lethargy, loss of appetite, or any localised signs of infection — require same-day veterinary assessment and empirical broad-spectrum antibiotic therapy.

Owners are instructed to take their cat’s rectal temperature at home during the nadir period (days 7 to 10 post-treatment) and to contact the oncology team immediately if fever is detected.

Gastrointestinal Effects

Nausea, vomiting, and reduced appetite are common in the 24 to 72 hours following each mitoxantrone treatment. These effects are generally transient and manageable. Most cats are pre-medicated with anti-nausea medication (maropitant, ondansetron, or metoclopramide) and sent home with additional doses for owner administration if needed.

Diarrhoea can also occur and typically peaks at the same time as nausea — 1 to 3 days post-treatment. Mild diarrhoea is managed with supportive care (bland diet, probiotics, maintaining hydration). Bloody diarrhoea or diarrhoea accompanied by systemic signs requires veterinary evaluation.

Urine Discolouration

Mitoxantrone is a deep blue-green compound. Urine may appear blue-green for 24 to 48 hours after treatment as the drug and its metabolites are excreted. This is expected and harmless — owners should be warned in advance to prevent unnecessary alarm.

Cardiotoxicity

Unlike doxorubicin, which carries a well-established dose-dependent cardiotoxicity risk in multiple species, mitoxantrone’s cardiotoxicity is considerably lower and is rarely a clinical concern in cats at standard veterinary doses. Cumulative dose monitoring is still maintained as a precaution, and cats with pre-existing significant cardiac disease should have a cardiac assessment before starting mitoxantrone.

Other Adverse Effects

• Alopecia (hair loss): Uncommon in cats compared to humans but can occur, particularly affecting whisker regrowth. Generally reversible after treatment completion.
• Local vein irritation: Can occur at the injection site. Rotation of injection sites and proper flushing technique minimise this.
• Immunosuppression: Beyond neutropenia, mitoxantrone broadly suppresses immune function. Avoid live vaccines during treatment; minimise exposure to sick animals.

Adverse Effect	Onset	Severity	Management
Neutropenia	Days 7–10 post-treatment	Potentially serious	Temperature monitoring at home; fever = same-day vet contact; antibiotics if febrile
Nausea / vomiting	24–72 hours post-treatment	Mild to moderate	Pre-medicate with maropitant; send home anti-emetics; small frequent meals
Diarrhoea	24–72 hours post-treatment	Mild to moderate	Bland diet; probiotics; IV fluids if severe; vet assessment if bloody
Blue-green urine	0–48 hours post-treatment	Harmless	Owner education in advance; no action needed
Reduced appetite	24–72 hours post-treatment	Mild to moderate	Appetite stimulants (mirtazapine); highly palatable food; monitor weight
Extravasation injury	During/immediately after infusion	Potentially severe	Stop infusion immediately; cold compress; vet assessment

Supporting Your Cat Through Treatment

Owner care between treatment cycles significantly impacts how well cats tolerate chemotherapy. Practical measures that improve quality of life and support recovery:

• Nutrition: Maintain caloric intake even during nausea periods. Offer small, frequent, highly palatable meals. Warmed food is often more appetising. Mirtazapine (transdermal or oral) is highly effective as an appetite stimulant in cats.
• Hygiene and infection prevention: During the neutropenic nadir period, minimise exposure to other animals, avoid boarding or grooming facilities, and maintain scrupulous litter tray hygiene. Wash hands before handling the cat.
• Stress minimisation: Chemotherapy visits can be stressful. Use a familiar blanket or towel with the cat’s home scent. Pre-visit anxiolytic medication (gabapentin or trazodone) can reduce travel and clinic-associated stress in anxious cats.
• Handling chemotherapy waste: Drug metabolites are excreted in urine and faeces for approximately 48 to 72 hours after treatment. Wear gloves when handling litter during this period; dispose of waste and soiled bedding appropriately; wash hands thoroughly after contact.

Assessing Response to Treatment

Response assessment typically occurs before each treatment cycle and uses a combination of:

• Physical examination — palpation of lymph nodes, abdominal organ size, general condition
• Abdominal ultrasound — assessment of intestinal wall thickness, lymph node size, organ infiltration
• Body weight and condition score — weight gain and improved muscle condition indicate response
• Owner-reported quality of life — appetite, energy level, social behaviour, litter tray habits

Response categories follow standard oncology criteria: complete remission (no detectable disease), partial remission (>50% reduction in tumour volume), stable disease, or progressive disease. Decisions about continuing, modifying, or discontinuing treatment are made at each reassessment point.

Key Takeaways

• Mitoxantrone is a DNA-intercalating chemotherapy agent used primarily for high-grade feline lymphoma, TCC, and as rescue therapy
• It is preferred over doxorubicin in cats due to significantly lower nephrotoxicity risk
• Standard protocol is 6–6.5 mg/m2 IV every 3 weeks; pre-treatment blood work is required before every cycle
• Neutropenia (days 7–10 post-treatment) is the primary serious adverse effect — owners must monitor temperature and contact the vet immediately if fever develops
• Blue-green urine for 24–48 hours after treatment is expected and harmless
• Chemotherapy metabolites are present in waste for 72 hours — wear gloves when handling litter during this period

References

1. Vail DM (2013). Feline lymphoma and leukaemia. In: Withrow and MacEwen’s Small Animal Clinical Oncology, 5th ed. Elsevier Saunders.

2. Moore AS et al. (1994). Doxorubicin and COP for treatment of feline lymphoma. J Vet Intern Med 8(1):9–15.

3. Peaston AE, Maddison JE (1999). Efficacy of doxorubicin as an induction agent for cats with lymphosarcoma. Aust Vet J 77(7):442–4.

4. Henry CJ et al. (2003). Antitumor activity of doxorubicin plus cyclophosphamide in cats with lymphoma. J Vet Intern Med 17(4):471–7.

5. Rassnick KM et al. (2008). Evaluation of mitoxantrone-based protocols in cats with lymphoma. J Vet Intern Med 22(1):156–64.

6. Plumb DC (2018). Plumb’s Veterinary Drug Handbook, 9th ed. Wiley-Blackwell.